DE60043125D1 - Zusammensetzungen und Verfahren für die Tumor-Behandlung - Google Patents
Zusammensetzungen und Verfahren für die Tumor-BehandlungInfo
- Publication number
- DE60043125D1 DE60043125D1 DE60043125T DE60043125T DE60043125D1 DE 60043125 D1 DE60043125 D1 DE 60043125D1 DE 60043125 T DE60043125 T DE 60043125T DE 60043125 T DE60043125 T DE 60043125T DE 60043125 D1 DE60043125 D1 DE 60043125D1
- Authority
- DE
- Germany
- Prior art keywords
- polypeptides
- present
- methods
- treatment
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 230000004544 DNA amplification Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13838599P | 1999-06-09 | 1999-06-09 | |
| US14479099P | 1999-07-20 | 1999-07-20 | |
| US14684399P | 1999-08-03 | 1999-08-03 | |
| US14818899P | 1999-08-10 | 1999-08-10 | |
| US14939699P | 1999-08-17 | 1999-08-17 | |
| US14932799P | 1999-08-17 | 1999-08-17 | |
| US14932099P | 1999-08-17 | 1999-08-17 | |
| US15011499P | 1999-08-20 | 1999-08-20 | |
| US15170099P | 1999-08-31 | 1999-08-31 | |
| US15173499P | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60043125D1 true DE60043125D1 (de) | 2009-11-19 |
Family
ID=27581055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60043125T Expired - Lifetime DE60043125D1 (de) | 1999-06-09 | 2000-05-15 | Zusammensetzungen und Verfahren für die Tumor-Behandlung |
| DE60042799T Expired - Lifetime DE60042799D1 (de) | 1999-06-09 | 2000-05-15 | Methoden zur Diagnose von Tumoren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60042799T Expired - Lifetime DE60042799D1 (de) | 1999-06-09 | 2000-05-15 | Methoden zur Diagnose von Tumoren |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP1683811B1 (OSRAM) |
| JP (5) | JP2003501087A (OSRAM) |
| AT (2) | ATE440109T1 (OSRAM) |
| AU (1) | AU4851900A (OSRAM) |
| CA (1) | CA2371434A1 (OSRAM) |
| DE (2) | DE60043125D1 (OSRAM) |
| ES (2) | ES2331657T3 (OSRAM) |
| WO (1) | WO2000075317A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034799A1 (en) * | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 6 human secreted proteins |
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6960651B2 (en) | 1999-06-29 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | TANGO 332 polypeptides |
| EP1194534A4 (en) * | 1999-06-29 | 2004-03-24 | Millennium Pharm Inc | NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS |
| WO2001047957A2 (en) * | 1999-12-29 | 2001-07-05 | Zymogenetics, Inc. | Human fgf-10- (kgf-2)-like protein zfgf-10 |
| AU5056501A (en) * | 2000-03-31 | 2001-10-08 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| US20040132021A1 (en) * | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
| US7332276B2 (en) * | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| CN103649118A (zh) | 2011-03-01 | 2014-03-19 | 安进公司 | 双特异性结合剂 |
| SG10201701634PA (en) | 2011-03-25 | 2017-04-27 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| AU2012290083B2 (en) | 2011-08-04 | 2017-07-20 | Amgen Inc. | Method for treating bone gap defects |
| BR112014016108A2 (pt) | 2011-12-28 | 2018-09-11 | Amgen Inc | método de tratamento de perda óssea alvelar |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN112166120B (zh) | 2018-03-30 | 2024-09-10 | 安姆根有限公司 | C末端抗体变体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| JP3399948B2 (ja) * | 1992-06-26 | 2003-04-28 | ザ トラスティーズ オブ プリンストン ユニバーシティ | Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法 |
| WO1995026201A1 (en) * | 1994-03-28 | 1995-10-05 | La Jolla Cancer Research Foundation | Brevican, a glial cell proteoglycan |
| US5635370A (en) * | 1994-04-08 | 1997-06-03 | Yale University | DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides |
| WO1999014327A2 (en) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer |
| US6653445B1 (en) * | 1997-01-21 | 2003-11-25 | Human Genome Sciences, Inc. | Human CCV polypeptides |
| AU733222B2 (en) * | 1997-11-25 | 2001-05-10 | Genentech Inc. | Fibroblast growth factor-19 |
| KR20010086224A (ko) * | 1998-01-23 | 2001-09-10 | 추후제출 | Ｍｅｔｈ1 및 ｍｅｔｈ2 폴리뉴클레오티드 및 폴리펩티드 |
| EP1194534A4 (en) * | 1999-06-29 | 2004-03-24 | Millennium Pharm Inc | NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS |
-
2000
- 2000-05-15 AU AU48519/00A patent/AU4851900A/en not_active Abandoned
- 2000-05-15 EP EP06001196A patent/EP1683811B1/en not_active Expired - Lifetime
- 2000-05-15 DE DE60043125T patent/DE60043125D1/de not_active Expired - Lifetime
- 2000-05-15 ES ES06001196T patent/ES2331657T3/es not_active Expired - Lifetime
- 2000-05-15 ES ES05024729T patent/ES2332916T3/es not_active Expired - Lifetime
- 2000-05-15 EP EP00930756A patent/EP1185642A2/en not_active Withdrawn
- 2000-05-15 DE DE60042799T patent/DE60042799D1/de not_active Expired - Lifetime
- 2000-05-15 CA CA002371434A patent/CA2371434A1/en not_active Abandoned
- 2000-05-15 AT AT06001196T patent/ATE440109T1/de not_active IP Right Cessation
- 2000-05-15 EP EP05024729A patent/EP1657256B1/en not_active Expired - Lifetime
- 2000-05-15 WO PCT/US2000/013358 patent/WO2000075317A2/en not_active Ceased
- 2000-05-15 AT AT05024729T patent/ATE444971T1/de not_active IP Right Cessation
- 2000-05-15 JP JP2001502580A patent/JP2003501087A/ja active Pending
-
2004
- 2004-06-24 JP JP2004186386A patent/JP4252501B2/ja not_active Expired - Fee Related
-
2005
- 2005-06-22 JP JP2005181534A patent/JP4260778B2/ja not_active Expired - Lifetime
- 2005-06-22 JP JP2005181588A patent/JP2006006332A/ja active Pending
- 2005-06-22 JP JP2005181558A patent/JP2006006331A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE444971T1 (de) | 2009-10-15 |
| EP1657256A3 (en) | 2006-08-09 |
| AU4851900A (en) | 2000-12-28 |
| EP1683811B1 (en) | 2009-08-19 |
| EP1185642A2 (en) | 2002-03-13 |
| EP1657256A2 (en) | 2006-05-17 |
| JP2003501087A (ja) | 2003-01-14 |
| JP2006006332A (ja) | 2006-01-12 |
| ES2332916T3 (es) | 2010-02-15 |
| JP4252501B2 (ja) | 2009-04-08 |
| WO2000075317A3 (en) | 2001-02-08 |
| JP4260778B2 (ja) | 2009-04-30 |
| WO2000075317A2 (en) | 2000-12-14 |
| EP1683811A3 (en) | 2006-10-11 |
| CA2371434A1 (en) | 2000-12-14 |
| EP1657256B1 (en) | 2009-10-07 |
| JP2006006330A (ja) | 2006-01-12 |
| JP2006006331A (ja) | 2006-01-12 |
| ES2331657T3 (es) | 2010-01-12 |
| EP1683811A2 (en) | 2006-07-26 |
| DE60042799D1 (de) | 2009-10-01 |
| JP2005027667A (ja) | 2005-02-03 |
| ATE440109T1 (de) | 2009-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1632499T3 (da) | Gensekvenser amplificeret i tumorer og diagnistiske anvendelser deraf | |
| WO2000053755A3 (en) | Compositions and methods for the treatment of tumor | |
| DE60043125D1 (de) | Zusammensetzungen und Verfahren für die Tumor-Behandlung | |
| DE69839571D1 (de) | Fibroblasten-wachstumsfaktor-19 | |
| DE69940964D1 (de) | Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums | |
| ATE357518T1 (de) | Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums | |
| KR100473550B1 (en) | Compositions and Methods for The Treatment of Tumor | |
| WO2000037640A3 (en) | Compositions and methods for the treatment of tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |